Novel Drug-Disease Modeling Framework for Oncology Benefit–Risk Evaluation: Application to Tusamitamab Ravtansinecpt: pharmacometrics & systems pharmacologyIF02026-01-290OAAI
Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trialsCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32024-04-011OAAI
Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasoneBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32021-11-266OA
Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive DisorderAAPS JOURNALIF3.72019-11-127OAAI
Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug ToxicologyTOXICOLOGICAL SCIENCESIF4.12018-05-213OAAI
Development and performance of npde for the evaluation of time-to-event modelsPHARMACEUTICAL RESEARCHIF4.32018-01-094PREAI
A sudden death risk score specifically for hypertension: based on 25648 individual patient data from six randomized controlled trialsJOURNAL OF HYPERTENSIONIF4.12017-11-013PREAI
DOES DIABETES REALLY HARM WOMEN MORE THAN MEN? ANALYSES FROM 30560 INDIVIDUAL PATIENT DATAJOURNAL OF HYPERTENSIONIF4.12017-09-010PREAI
THE FIRST RISK SCORING SYSTEM FOR SUDDEN DEATH PREDICTION IN PRIMARY PREVENTION PATIENTSJOURNAL OF HYPERTENSIONIF4.12016-09-010PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向